The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes. Drugs (Pharmaceuticals), GLP-1 RAs (Drug), Weight, Regulation and Deregulation of Industry, Stocks and Bonds, Ozempic (Drug), Company Reports, Appointments and Executive Changes Read More
How Ozempic Maker Novo Nordisk Lost Its Shine
